rebel Financial rebel Financial
← All Posts
TBPH

Theravance Biopharma, Inc.

June 13, 2026 • Author: Phil Ratcliff • TBPH
Item Proposal Vote
1 Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified
1.01 Laurie Smaldone Alsup ✓ For
1.02 Susannah Gray ✓ For
1.03 Dean J. Mitchell ✓ For
1.04 Donal O’Connor ✓ For
1.05 Deepika R. Pakianathan ✓ For
1.06 Rick E Winningham ✗ Against
2 Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2026. ✓ For
3 Approve the non-binding advisory resolution regarding the compensation of our named executive officers. ✓ For
Attachments
📄
TBPH_2025_10k.pdf 1.4 MB
📄
TBPH_Proxy_Statement.pdf 0.9 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.